Literature DB >> 16980511

Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity.

Xiuli Yang1, Yiwei Chu, Ying Wang, Ruihua Zhang, Sidong Xiong.   

Abstract

Although it is known that the chemoattractant effect of IFN-gamma inducible protein 10 (IP-10), a CXC chemokine (CXCL10), plays an important role in T cell-mediated antitumor immunity in vivo, whether IP-10 is involved in modulating the proliferation, survival and functional activation of tumor-specific T cells remains poorly investigated. Using an experimental mouse tumor model, we demonstrated that the in vivo growth of 4T1 tumor cells harboring IP-10 gene (4T1-IP-10) was inhibited. Mice inoculated with 4T1-IP-10 tumor cells expressing functional IP-10 survived over 90 days, whereas mice injected with control parental 4T1 cells and mice of control 4T1 cells transduced with control plasmid all succumbed to the tumor by day 38 after tumor inoculation. Mechanical analysis showed that targeted expression of IP-10 in 4T1 tumor cells markedly enhanced the infiltration of tumor-specific T cells into the 4T1-IP-10 tumor. These tumor infiltrating T lymphocytes (TILs) recruited by IP-10 were potent cytolytic killers against 4T1 tumor cells and were able to proliferate and produce high levels of IFN-gamma in response to 4T1 cells. In vivo administration of IP-10-recruited TILs induced vigorous proliferation of these TILs in situ in the 4T1-IP-10 tumor but not in the 4T1-pcDNA3 and parental 4T1 tumors. Furthermore, culture of TILs together with recombinant IP-10 significantly enhanced the proliferation and expansion of IP-10-recruited TILs in response to 4T1 tumor antigens. These results suggest that IP-10 is not only able to chemoattract tumor-specific T cells into the local tissue, but also enhance the proliferation, survival, and functional activation of these TILs, leading to the tumor regression. Thus, targeted expression of IP-10 in vivo will allow for the development of a novel approach for immunotherapy of tumor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980511     DOI: 10.1189/jlb.0306212

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  21 in total

Review 1.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.

Authors:  Ryuma Tokunaga; Wu Zhang; Madiha Naseem; Alberto Puccini; Martin D Berger; Shivani Soni; Michelle McSkane; Hideo Baba; Heinz-Josef Lenz
Journal:  Cancer Treat Rev       Date:  2017-11-26       Impact factor: 12.111

2.  Close resemblance between chemokine receptor expression profiles of lymphoproliferative disease of granular lymphocytes and their normal counterparts in association with elevated serum concentrations of IP-10 and MIG.

Authors:  Kayoko Momose; Hideki Makishima; Toshiro Ito; Hideyuki Nakazawa; Shigetaka Shimodaira; Kendo Kiyosawa; Fumihiro Ishida
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

3.  Direct gene transfer with IP-10 mutant ameliorates mouse CVB3-induced myocarditis by blunting Th1 immune responses.

Authors:  Yan Yue; Jun Gui; Wenqing Ai; Wei Xu; Sidong Xiong
Journal:  PLoS One       Date:  2011-03-22       Impact factor: 3.240

4.  NF-kappaB-dependent synergistic regulation of CXCL10 gene expression by IL-1beta and IFN-gamma in human intestinal epithelial cell lines.

Authors:  Sunil Yeruva; Giuliano Ramadori; Dirk Raddatz
Journal:  Int J Colorectal Dis       Date:  2007-11-28       Impact factor: 2.571

5.  Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity.

Authors:  Robert P Edwards; Pawel Kalinski; Anda M Vlad; Brian Orr; Haider Mahdi; Yusi Fang; Mary Strange; Ibrahim Uygun; Mainpal Rana; Lixin Zhang; Adria Suarez Mora; Alexandra Pusateri; Esther Elishaev; Chaeryon Kang; George Tseng; William Gooding
Journal:  Clin Cancer Res       Date:  2022-05-13       Impact factor: 13.801

6.  Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.

Authors:  Mark R Middleton; Cheryl McAlpine; Victoria K Woodcock; Pippa Corrie; Jeffrey R Infante; Neil M Steven; Thomas R Jeffry Evans; Alan Anthoney; Alexander N Shoushtari; Omid Hamid; Avinash Gupta; Antonella Vardeu; Emma Leach; Revashnee Naidoo; Sarah Stanhope; Sion Lewis; Jacob Hurst; Ita O'Kelly; Mario Sznol
Journal:  Clin Cancer Res       Date:  2020-08-18       Impact factor: 13.801

7.  Adipokines and obesity are associated with colorectal polyps in adult males: a cross-sectional study.

Authors:  Sarah S Comstock; Kari Hortos; Bruce Kovan; Sarah McCaskey; Dorothy R Pathak; Jenifer I Fenton
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

8.  Downregulation of MMP2 and Bcl-2 in Adipose Derived Stem Cells (ASCs) following Transfection with IP-10 Gene.

Authors:  Mahboobeh Razmkhah; Mansooreh Jaberipour; Abbas Ghaderi
Journal:  Avicenna J Med Biotechnol       Date:  2014-01

9.  Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.

Authors:  Victoria E Shaw; Brian Lane; Claire Jenkinson; Trevor Cox; William Greenhalf; Christopher M Halloran; Joseph Tang; Robert Sutton; John P Neoptolemos; Eithne Costello
Journal:  Mol Cancer       Date:  2014-05-20       Impact factor: 27.401

Review 10.  Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment.

Authors:  Naofumi Mukaida; So-ichiro Sasaki; Tomohisa Baba
Journal:  Mediators Inflamm       Date:  2014-05-22       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.